Results 41 to 50 of about 11,332,305 (264)

Amyloid PET:A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials [PDF]

open access: yes, 2022
Using amyloid PET imaging as a single primary surrogate efficacy measure in Alzheimer's disease immunotherapy trials, as happened when the FDA granted accelerated approval of aducanumab, is unjustified.
Høilund-Carlsen, Poul F   +4 more
core   +1 more source

Unblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials [PDF]

open access: yesEuropean Journal of Neurology, 2020
A disease modifying therapy for Alzheimer's disease is one of the highest priorities in medicine. Dozens of amyloid-modifying trials have failed to meet primary endpoints. Aducanumab, a monoclonal anti-amyloid antibody, lowers plaque burden. Early findings suggested a slowing of cognitive deterioration(1).
A. Gleason, S. Ayton, A. I. Bush
openaire   +2 more sources

Insular volume abnormalities associated with different transition probabilities to psychosis [PDF]

open access: yes, 2011
Background Although individuals vulnerable to psychosis show brain volumetric abnormalities, structural alterations underlying different probabilities for later transition are unknown.
McGuire, P.   +52 more
core   +2 more sources

Symptomatic amyloid-related imaging abnormalities after Lecanemab treatment in an APOE ε4 homozygous patient with mild cognitive impairment due to Alzheimer's disease: one case report

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery
Objective To report a case of symptomatic amyloid-related imaging abnormalities (ARIA) following Lecanemab treatment in patient with mild cognitive impairment due to Alzheimer's disease (AD-MCI), so as to provide references for the clinical safe ...
CAO Wen-wei   +5 more
doaj   +1 more source

Resting State fMRI Reveals Diminished Functional Connectivity in a Mouse Model of Amyloidosis [PDF]

open access: yes, 2013
Introduction: Functional connectivity (FC) studies have gained immense popularity in the evaluation of several neurological disorders, such as Alzheimer’s disease (AD). AD is a complex disorder, characterised by several pathological features. The problem
Rafael Delgado Y Palacios   +36 more
core   +2 more sources

Parenchymal and vascular Aβ-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease [PDF]

open access: yes, 2008
The deposition of the amyloid β-protein (Aβ) is one of the pathological hallmarks of Alzheimer's disease (AD). Aβ-deposits show the morphology of senile plaques and cerebral amyloid angiopathy (CAA). Senile plaques and vascular Aβ-deposits occur first in
Griffin, W. Sue T.   +3 more
core   +1 more source

Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA

open access: yes, 2023
Anti-amyloid therapies (AATs), such as anti-amyloid monoclonal antibodies, are emerging treatments for people with early Alzheimer’s disease (AD). AATs target amyloid β plaques in the brain.
Nho, Kwangsik   +9 more
core   +1 more source

A fluorescent amyloid sensor for quantitative super-resolution imaging of amyloid fibril assembly. [PDF]

open access: yes, 2021
Many soluble proteins can self-assemble into macromolecular structures called amyloids, a subset of which are implicated in a range of neurodegenerative disorders.
Liam D., Adair   +4 more
core   +2 more sources

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

open access: yesFEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee   +2 more
wiley   +1 more source

Imaging for anti‐amyloid therapy eligibility: Comparing GRE and SWI in detecting microhemorrhages and superficial siderosis

open access: yesAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Anti‐amyloid therapies such as lecanemab require magnetic resonance imaging (MRI) screening to exclude patients with > 4 gradient‐recalled echo (GRE)‐detected microhemorrhages or any superficial siderosis (SS).
Jeremy N. Ford   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy